Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra V Navarra

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Kidney International|November 14, 2018
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritisBrad H Rovin, Neil Solomons, William F Pendergraft, et al.
Rheumatology (Oxford, England)|July 15, 2019
Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extensionRonald F van Vollenhoven, Sandra V Navarra, Roger A Levy, et al.
The Lancet. Rheumatology|November 25, 2024
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trialAnca D Askanase, David D'Cruz, Kenneth Kalunian, et al.
International Journal of Rheumatic Diseases|August 10, 2021
Rheumatoid arthritis management in the APLAR region: Perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseasesArvind Chopra, Hsiao-Yi Lin, Sandra V Navarra, et al.
Annals of the Rheumatic Diseases|October 14, 2015
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Kate Franklyn, Chak Sing Lau, Sandra V Navarra, et al.
Annals of the Rheumatic Diseases|January 12, 2012
Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-GMichelle M A Fernando, Jan Freudenberg, Annette Lee, et al.
Annals of the Rheumatic Diseases|May 3, 2012
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsSusan Manzi, Jorge Sánchez-Guerrero, Joan T Merrill, et al.
Journal of Pain Research|August 22, 2020
Practice Advisory on the Appropriate Use of NSAIDs in Primary CareKok Yuen Ho, Mary S Cardosa, Sumapa Chaiamnuay, et al.
Arthritis Care & Research|September 28, 2019
Associations Between Classification Criteria Items in Systemic Lupus ErythematosusZahi Touma, Ricard Cervera, Ralph Brinks, et al.
Nephrology (Carlton, Vic.)|July 24, 2013
Overview of lupus nephritis management guidelines and perspective from AsiaChi Chiu Mok, Desmond Yh Yap, Sandra V Navarra, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Kidney International|November 14, 2018
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritisBrad H Rovin, Neil Solomons, William F Pendergraft, et al.
Rheumatology (Oxford, England)|July 15, 2019
Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extensionRonald F van Vollenhoven, Sandra V Navarra, Roger A Levy, et al.
The Lancet. Rheumatology|November 25, 2024
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trialAnca D Askanase, David D'Cruz, Kenneth Kalunian, et al.
International Journal of Rheumatic Diseases|August 10, 2021
Rheumatoid arthritis management in the APLAR region: Perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseasesArvind Chopra, Hsiao-Yi Lin, Sandra V Navarra, et al.
Annals of the Rheumatic Diseases|October 14, 2015
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Kate Franklyn, Chak Sing Lau, Sandra V Navarra, et al.
Annals of the Rheumatic Diseases|January 12, 2012
Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-GMichelle M A Fernando, Jan Freudenberg, Annette Lee, et al.
Annals of the Rheumatic Diseases|May 3, 2012
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsSusan Manzi, Jorge Sánchez-Guerrero, Joan T Merrill, et al.
Journal of Pain Research|August 22, 2020
Practice Advisory on the Appropriate Use of NSAIDs in Primary CareKok Yuen Ho, Mary S Cardosa, Sumapa Chaiamnuay, et al.
Arthritis Care & Research|September 28, 2019
Associations Between Classification Criteria Items in Systemic Lupus ErythematosusZahi Touma, Ricard Cervera, Ralph Brinks, et al.
Nephrology (Carlton, Vic.)|July 24, 2013
Overview of lupus nephritis management guidelines and perspective from AsiaChi Chiu Mok, Desmond Yh Yap, Sandra V Navarra, et al.
Pageof 5